WO2021112217A1

WO2021112217A1 - Composition for suppressing increase in amount of neutral fat in liver

Info

Publication number: WO2021112217A1
Application number: PCT/JP2020/045224
Authority: WO
Inventors: しのぶ秋好; 遥大橋; 泰世須賀
Original assignee: 味の素株式会社
Priority date: 2019-12-05
Filing date: 2020-12-04
Publication date: 2021-06-10

Abstract

The present invention addresses the problem of providing a composition (e.g., a fatty liver suppression composition) for suppressing increases in the amount of neutral fat in the liver, a composition for improving insulin resistance, and a composition for suppressing increases in amount of visceral fat.　A composition (e.g., a fatty liver suppression composition) for suppressing increases in the amount of neutral fat in the liver, the composition containing, as active ingredients, tyrosine, serine, alanine, aspartic acid, and glutamic acid. A composition (e.g., a fatty liver suppression composition) for suppressing increases in the amount of neutral fat in the liver, a composition for improving insulin resistance, and a composition for suppressing increases in amount of visceral fat, the compositions containing, as active ingredients, tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine, and cystine.

Description

Composition for suppressing increase in triglyceride mass in liver

The present invention comprises a composition containing a specific amino acid for suppressing an increase in the amount of triglyceride in the liver (for example, a composition for suppressing fatty liver), a composition for improving insulin resistance, and visceral fat. It relates to a composition for suppressing an increase in the amount.

For fatty liver, there are no medicines or supplements that have a direct effect, and exercise therapy and diet therapy are recommended, but the effect is not sufficient and the effect is direct for fatty liver. There is a need to develop certain medicines and supplements.
In Non-Patent Document 1, the effects of leucine and valine on hepatic lipid accumulation in dietary obesity model mice are investigated. In Non-Patent Document 2, the effect of ketogenic essential amino acids on hepatic lipogenesis (DNL) is investigated.
However, it is not known that the specific amino acid composition of the present invention described later suppresses the increase in triglyceride mass in the liver, improves insulin resistance, and suppresses the increase in visceral fat mass.

An object of the present invention is to provide a composition for suppressing an increase in the amount of triglyceride in the liver (for example, a composition for suppressing fatty liver).
Another object of the present invention is to provide a composition for improving insulin resistance and a composition for suppressing an increase in visceral fat mass.

The present inventors conducted diligent studies in order to solve the above-mentioned problems, and found that the composition containing a specific amino acid described later as an active ingredient (the composition (I) of the present invention) was neutral in the liver. It has been found that the increase in triglyceride mass is suppressed, and a composition containing a specific amino acid described later (composition (II) of the present invention) suppresses the increase in triglyceride mass in the liver, insulin resistance. We have found that it improves sex and suppresses the increase in visceral fat mass, and further investigated it to complete the present invention.

That is, the present invention provides the following.
[1] A composition containing tyrosine, serine, alanine, aspartic acid and glutamic acid as active ingredients for suppressing an increase in the amount of triglyceride in the liver.
[2] The composition according to the above [1], which is used for suppressing fatty liver.
[3] When tyrosine is 1 part by weight, serine is 0.4 to 1.5 parts by weight, alanine is 0.4 to 1.5 parts by weight, and aspartic acid is 0.5 to 1.5 parts by weight. The composition according to the above [1] or [2], which is 0.4 to 2.5 parts by weight of glutamic acid.
[4] The composition according to any one of the above [1] to [3], which is a food product.
[5] A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine as active ingredients for suppressing an increase in the amount of triglyceride in the liver.
[6] The composition according to the above [5], which is used for suppressing fatty liver.
[7] A composition for improving insulin resistance, which contains tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine as active ingredients.
[8] A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine as active ingredients for suppressing an increase in visceral fat mass.
[9] When tyrosine is 1 part by weight, the blending ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, and 0.5 to 1.5 parts by weight of aspartic acid. The composition according to any one of the above [5] to [8], which is 0.4 to 2.5 parts by weight of glutamic acid, 1 to 4 parts by weight of isoleucine, and 0.1 to 2 parts by weight of cystine.
[10] The composition according to any one of the above [5] to [9], which is a food product.

[11] A subject in need of suppressing an increase in triglyceride mass in the liver, which comprises administering a composition containing an effective amount of tyrosine, serine, alanine, aspartic acid and glutamic acid. A method of suppressing an increase in triglyceride mass.
[12] The method according to the above [11], wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
[13] When tyrosine is 1 part by weight, serine is 0.4 to 1.5 parts by weight, alanine is 0.4 to 1.5 parts by weight, and aspartic acid is 0.5 to 1.5 parts by weight. The method according to the above [11] or [12], which is 0.4 to 2.5 parts by weight of glutamic acid and glutamic acid.
[14] The method according to any one of [11] to [13] above, wherein the composition is orally administered to a subject.
[15] A composition containing effective amounts of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine is administered to a subject who needs to suppress an increase in triglyceride mass in the liver. A method of suppressing an increase in triglyceride mass in the liver in a subject.
[16] The method according to the above [15], wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
[17] Insulin resistance in a subject in need of improved insulin resistance, including administration of a composition containing an effective amount of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine. How to improve.
[18] Viscera in a subject in need of suppression of an increase in visceral fat mass, comprising administering to a subject a composition containing effective amounts of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine. A method of suppressing an increase in fat mass.
[19] When tyrosine is 1 part by weight, the blending ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, and 0.5 to 1.5 parts by weight of aspartic acid. The method according to any one of [15] to [18] above, which comprises 0.4 to 2.5 parts by weight of glutamic acid, 1 to 4 parts by weight of isoleucine, and 0.1 to 2 parts by weight of cystine.
[20] The method according to any one of [15] to [19] above, wherein the composition is orally administered to a subject.

[21] A composition containing tyrosine, serine, alanine, aspartic acid and glutamic acid for use in suppressing an increase in triglyceride mass in the liver.
[22] The composition according to the above [21], wherein the suppression of an increase in the amount of triglyceride in the liver is fatty liver suppression.
[23] Assuming that tyrosine is 1 part by weight, serine is 0.4 to 1.5 parts by weight, alanine is 0.4 to 1.5 parts by weight, and aspartic acid is 0.5 to 1.5 parts by weight. The composition according to the above [21] or [22], which is 0.4 to 2.5 parts by weight of glutamic acid and glutamic acid.
[24] The composition according to any one of the above [21] to [23], which is a food product.
[25] A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine for use in suppressing the increase in triglyceride mass in the liver.
[26] The composition according to the above [25], wherein the suppression of an increase in the amount of triglyceride in the liver is fatty liver suppression.
[27] A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine for use in improving insulin resistance.
[28] A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine for use in suppressing an increase in visceral fat mass.
[29] When tyrosine is 1 part by weight, the blending ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, and 0.5 to 1.5 parts by weight of aspartic acid. The composition according to any one of the above [25] to [28], which is 0.4 to 2.5 parts by weight of glutamic acid, 1 to 4 parts by weight of isoleucine, and 0.1 to 2 parts by weight of cystine.
[30] The composition according to any one of the above [25] to [29], which is a food product.

[31] Use of tyrosine, serine, alanine, aspartic acid and glutamic acid to produce compositions for suppressing the increase in triglyceride mass in the liver.
[32] The use according to the above [31], wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
[33] When tyrosine is 1 part by weight, serine is 0.4 to 1.5 parts by weight, alanine is 0.4 to 1.5 parts by weight, and aspartic acid is 0.5 to 1.5 parts by weight. The use according to the above [31] or [32], which is 0.4 to 2.5 parts by weight of glutamic acid and glutamic acid.
[34] The use according to any one of the above [31] to [33], wherein the composition is a food product.
[35] Use of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine to produce compositions for suppressing the increase in triglyceride mass in the liver.
[36] The use according to the above [35], wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
[37] Use of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine to produce compositions for improving insulin resistance.
[38] Use of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine to produce compositions for suppressing the increase in visceral fat mass.
[39] When tyrosine is 1 part by weight, the blending ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, and 0.5 to 1.5 parts by weight of aspartic acid. The use according to any one of the above [35] to [38], which is 0.4 to 2.5 parts by weight of glutamic acid, 1 to 4 parts by weight of isoleucine and 0.1 to 2 parts by weight of cystine.
[40] The use according to any one of the above [35] to [39], wherein the composition is a food product.

INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide a composition for suppressing an increase in the amount of triglyceride in the liver (for example, a composition for suppressing fatty liver).
Further, according to the present invention, it is possible to provide a composition for improving insulin resistance and a composition for suppressing an increase in visceral fat mass.

FIG. 1 shows the results of Test Example 1. FIG. 2 shows the results of Test Example 2. FIG. 3 shows the results of Test Example 3. FIG. 4 shows the results of Test Example 4.

The composition for suppressing an increase in the amount of neutral fat in the liver of the present invention is a composition containing tyrosine, serine, alanine, aspartic acid and glutamic acid as active ingredients (in the present specification, tyrosine and serine). , Alanine, aspartic acid and glutamic acid may be referred to as the composition (I) of the present invention).
The composition (I) of the present invention is useful as a composition for suppressing fatty liver because it suppresses an increase in the amount of triglyceride in the liver.

As a preferred embodiment of the present invention, the composition for suppressing an increase in the amount of neutral fat in the liver of the present invention contains tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine as active ingredients. (In the present specification, a composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine may be referred to as the composition (II) of the present invention).
The composition (II) of the present invention is useful as a composition for suppressing fatty liver because it suppresses an increase in the amount of triglyceride in the liver.
The composition (II) of the present invention is also useful as a composition for improving insulin resistance.
Furthermore, the composition (II) of the present invention is also useful as a composition for suppressing an increase in visceral fat mass.

In the present invention, "suppressing the increase in the amount of triglyceride in the liver" means that the amount of triglyceride in the liver (particularly, the amount of triglyceride) increases due to diet, aging, illness, obesity, constitution and the like. , Prevention, approaching or returning to normal, preventing exacerbations.
In the present invention, "fatty liver suppression" means preventing, bringing the fatty liver closer to normal, returning it to normal, or preventing exacerbation.
In the present invention, "improving insulin resistance" means preventing, bringing back or returning to normal insulin resistance, or preventing exacerbation due to diet, aging, illness, obesity, constitution, etc. To do.
As used herein, "insulin resistance" refers to insulin because even if insulin is secreted from the pancreas into the blood, the response to insulin in the liver, skeletal muscle, and adipose tissue is slowed down (decreased sensitivity). It is a condition in which the function of lowering blood sugar is not fully exerted (insulin does not work well). Therefore, since insulin secretion is required more, the blood insulin concentration becomes high.
In the present invention, "suppressing the increase in visceral fat mass" means preventing, approaching, returning, or exacerbating the increase in visceral fat mass due to diet, aging, illness, obesity, constitution, etc. It means to prevent.
"Composition for suppressing increase in triglyceride mass of liver" (for example, composition for suppressing fatty liver), "Composition for improving insulin resistance", "Increase in visceral fat mass" of the present invention. The use of the "composition for suppressing" may be therapeutic or non-therapeutic use for subjects such as humans. Here, "non-therapeutic" is a concept that does not include medical practice, that is, a concept that does not include a method of surgery, treatment, or diagnosis of a human being.

The composition (I) of the present invention contains tyrosine, serine, alanine, aspartic acid and glutamic acid as active ingredients.
The composition (II) of the present invention contains tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine as active ingredients.
Hereinafter, the compositions (I) and (II) of the present invention are collectively referred to as the compositions of the present invention.

The amino acids contained in the composition of the present invention are not limited as long as the effects of the present invention are not impaired, but L-form or DL-form is preferable, and L-form is more preferable.

The amino acid in the present invention may be produced by any production method such as a protein hydrolysis method, a chemical synthesis method, an enzyme method or a fermentation method, or a commercially available product may be used.

The amino acid in the present invention can also be obtained by enzymatically hydrolyzing a natural protein having the amino acid sequence.

As the amino acid in the present invention, it can be used not only in the form of a free form but also in the form of a salt. The terms tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine in the present specification are concepts that also include salts, respectively. The form of the salt is not particularly limited as long as it is a salt that is acceptable as food or a salt that is pharmacologically acceptable, and examples thereof include acid addition salts and salts with bases.
Specific examples thereof include inorganic bases, organic bases, inorganic acids, salts with organic acids, and salts with amino acids.

Examples of the salt with an inorganic base include salts with alkali metals such as lithium, sodium and potassium, salts with alkaline earth metals such as magnesium and calcium, and ammonium salts.
Examples of the salt with an organic base include salts with alkanolamines such as monoethanolamine, diethanolamine and triethanolamine, and salts with heterocyclic amines such as morpholine and piperidine.
Examples of the salt with the inorganic acid include salts with hydrochloric acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid, and the like.
Examples of salts with organic acids include salts with monocarboxylic acids such as formic acid, acetic acid and propanoic acid; salts with saturated dicarboxylic acids such as oxalic acid, malonic acid, malic acid and succinic acid; maleic acid and fumaric acid. Salts with unsaturated dicarboxylic acids such as; salts with tricarboxylic acids such as citric acid; salts with ketoic acids such as α-ketoglutaric acid and the like.
Salts with amino acids include salts with aliphatic amino acids such as glycine and alanine; salts with aromatic amino acids such as tyrosine; salts with basic amino acids such as arginine; salts with acidic amino acids such as aspartic acid and glutamic acid. Examples include salts with amino acids that form lactam, such as pyroglutamic acid.

The above-mentioned salts may be hydrates (hydrous salts), and examples of such hydrates include monohydrate to hexahydrate.

As each amino acid in the present invention, one kind of free form and the above-mentioned salt form may be used alone, or two or more kinds may be used in combination.
In the present invention, tyrosine is preferably a free form, serine is preferably a free form, alanine is preferably a free form, aspartic acid is preferably a free form and a sodium salt, and glutamic acid is preferably a free form and a sodium salt. Etc., isoleucine is preferably a free form, and cystine is preferably a free form.

In the composition (I) of the present invention, the blending ratio of tyrosine, serine, alanine, aspartic acid and glutamic acid is usually (2) in terms of L-form and free form, assuming that tyrosine is 1 part by weight. 0.4 to 1.5 parts by weight of serine, (3) 0.4 to 1.5 parts by weight of alanine, (4) 0.5 to 1.5 parts by weight of aspartic acid, (5) 0.4 to 2 parts by weight of glutamic acid. It is 5 parts by weight, preferably (2) 0.4 to 1.3 parts by weight, (3) 0.4 to 1.3 parts by weight, (4) 0.7 to 1.3 parts by weight, and (5). ) 0.4 to 2.1 parts by weight, more preferably (2) 0.4 to 1.1 parts by weight, (3) 0.4 to 1.1 parts by weight, (4) 0.9 to 0.9 parts. 1.1 parts by weight, (5) 0.4 to 2.1 parts by weight.

The weight (%) of each amino acid in the composition (I) of the present invention is usually (1) tyrosine in terms of L-form and free form with respect to the total amount of tyrosine, serine, alanine, aspartic acid and glutamic acid. 12-40% by weight, (2) serine 12-28% by weight, (3) alanine 12-28% by weight, (4) aspartic acid 12-40% by weight and (5) glutamic acid 12-30% by weight, preferably. (1) 14 to 30% by weight, (2) 14 to 25% by weight, (3) 14 to 25% by weight, (4) 14 to 30% by weight and (5) 12 to 30% by weight, more preferably ( 1) 14 to 29% by weight, (2) 14 to 22% by weight, (3) 14 to 22% by weight, (4) 18 to 29% by weight, and (5) 13 to 30% by weight.

Here, the amino acids in the present invention (compositions (I) and (II) of the present invention) mean free amino acids and do not include constituent amino acids in proteins and peptides. Further, in the present specification, the content and compounding ratio of each amino acid in the present invention are the content and compounding ratio of L-form amino acids, and when the amino acid is contained in the form of a salt, it is converted into a free form. It is expressed by the content of the product. The amino acid composition of the present invention may contain a D-form amino acid. When the DL-form (L-form: D-form = 1: 1) amino acid is contained, the conversion can be performed based on the amino acid content and blending ratio of the L-form. For example, when DL-alanine is contained in an amount of 28% by weight, the L-form conversion value is 14% by weight.

The dose (intake) of the composition (I) of the present invention may vary depending on age, sex, body weight, target disease, symptom, and dosage form, but is usually from 1 g per day for an adult (for example, body weight 60 kg). It is administered or ingested once or several times a day so as to be in the range of 30 g, preferably 2 g to 15 g, and more preferably 2 g to 12 g.

Further, in the composition (I) of the present invention, the dose (intake) of tyrosine is usually in the range of 0.28 g to 8.6 g per day for an adult, preferably in the range of 0.57 g to 4.3 g. , 0.57 g to 3.5 g is more preferable.
In the composition (I) of the present invention, the dose (intake) of serin is usually in the range of 0.14 g to 4.2 g, preferably in the range of 0.28 g to 2.2 g, and is 0. The range of .28 g to 1.8 g is more preferable.
In the composition (I) of the present invention, the dose (intake) of alanine is usually in the range of 0.14 g to 4.2 g, preferably in the range of 0.28 g to 2.2 g, and is 0. The range of .28 g to 1.8 g is more preferable.
In the composition (I) of the present invention, the dose (intake) of aspartic acid is usually in the range of 0.28 g to 8.6 g, preferably in the range of 0.57 g to 4.3 g per day for adults. The range of 0.57 g to 3.5 g is more preferable.
In the composition (I) of the present invention, the dose (intake) of glutamic acid is usually in the range of 0.14 g to 4.2 g, preferably in the range of 0.28 g to 2.2 g, and is 0. The range of .28 g to 1.8 g is more preferable.
The amount per adult can be appropriately changed in consideration of physical conditions such as gender, age, and disease.

In the composition (I) of the present invention, the above-mentioned daily amount can be administered (ingested) at one time or in several divided doses. The administration period (intake period) is not particularly limited, and long-term administration (long-term ingestion) is possible because the active ingredient is an amino acid.

In the composition (I) of the present invention, the ratio contained in the composition of amino acids other than tyrosine, serine, alanine, aspartic acid and glutamic acid in the present invention is converted into a free form with respect to the total weight of the composition. Therefore, it is 50% by weight or less, preferably 40% by weight or less, more preferably 30% by weight or less, further preferably not substantially contained, and particularly preferably not contained. The term "substantially free" means 0.2% by weight or less, preferably 0.1% by weight or less, and more preferably 0.05% by weight or less.

The composition (I) of the present invention can further contain other nutritional components such as sugars, lipids, proteins, vitamins and minerals in addition to the amino acids in the present invention.

In addition to tyrosine, serine, alanine, aspartic acid and glutamate, the composition (I) of the present invention is optionally other amino acids, other nutritional components, food-acceptable additives, and pharmaceutically acceptable. Additives, etc., and use a formulation method well known in the field of formulation, for example, the method described in each article of the 17th Amendment of the Japanese Pharmacy Regulations [3] Formulation, to make solutions, suspensions, and emulsions. It can be in various forms such as liquid such as liquid; semi-solid such as gel and cream; and solid such as powder, granules, tablets and capsules.

In the composition (II) of the present invention, the blending ratio of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine is (1) when tyrosine is 1 part by weight, it is converted into L form and free form. Usually (2) 0.4 to 1.5 parts by weight of serine, (3) 0.4 to 1.5 parts by weight of alanine, (4) 0.5 to 1.5 parts by weight of aspartic acid, (5) 0. 4 to 2.5 parts by weight, (6) 1 to 4 parts by weight of isoleucine, (7) 0.1 to 2 parts by weight of cystine, preferably (2) 0.4 to 1.3 parts by weight of serine, ( 3) 0.4 to 1.3 parts by weight of alanine, (4) 0.7 to 1.3 parts by weight of aspartic acid, (5) 0.4 to 2.1 parts by weight of glutamate, (6) 2 to 3 parts by weight of isoleucine Parts, (7) 0.5 to 1.5 parts by weight of cystine, more preferably 0.4 to 1.1 parts by weight of serine, (3) 0.4 to 1.1 parts by weight of alanine. (4) 0.9 to 1.1 parts by weight of aspartic acid, (5) 0.4 to 2.1 parts by weight of glutamate, (6) 2 to 3 parts by weight of isoleucine, (7) 0.5 to 1.5 parts of cystine It is a part by weight.

The weight (%) of each amino acid in the composition (II) of the present invention is usually converted into L form and free form with respect to the total amount of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine. (1) Tyrosine 10 to 20% by weight, (2) Serine 5 to 10% by weight, (3) Alanine 5 to 10% by weight, (4) Aspartic acid 10 to 20% by weight, (5) Glutamic acid 5 to 10% by weight , (6) 30-40% by weight of isoleucine, (7) 10-20% by weight of cystine, preferably (1) 12-18% by weight of tyrosine, (2) 5-10% by weight of serine, (3) 5 to 10% by weight of alanine. 10% by weight, (4) aspartic acid 12-18% by weight, (5) glutamic acid 5-10% by weight, (6) isoleucine 30-38% by weight and (7) cystine 12-18% by weight.

The dose (intake) of the composition (II) of the present invention may vary depending on age, sex, body weight, target disease, symptom, and dosage form, but is usually from 1 g per day for an adult (for example, body weight 60 kg). It is administered or ingested once or several times a day so as to be in the range of 30 g, preferably 2 g to 15 g, and more preferably 2 g to 12 g.

Further, in the composition (II) of the present invention, the dose (intake) of tyrosine is usually in the range of 0.28 g to 8.6 g per day for an adult, preferably in the range of 0.57 g to 4.3 g. , 0.57 g to 3.5 g is more preferable.
In the composition (II) of the present invention, the dose (intake) of serin is usually in the range of 0.14 g to 4.2 g, preferably in the range of 0.28 g to 2.2 g, and is 0. The range of .28 g to 1.8 g is more preferable.
In the composition (II) of the present invention, the dose (intake) of alanine is usually in the range of 0.14 g to 4.2 g, preferably in the range of 0.28 g to 2.2 g, and is 0. The range of .28 g to 1.8 g is more preferable.
In the composition (II) of the present invention, the dose (intake) of aspartic acid is usually in the range of 0.28 g to 8.6 g, preferably in the range of 0.57 g to 4.3 g per day for adults. The range of 0.57 g to 3.5 g is more preferable.
In the composition (II) of the present invention, the dose (intake) of glutamic acid is usually in the range of 0.14 g to 4.2 g, preferably in the range of 0.28 g to 2.2 g, and is 0. The range of .28 g to 1.8 g is more preferable.
In the composition (II) of the present invention, the dose (intake) of isoleucine is usually in the range of 0.7 g to 21 g, preferably in the range of 0.7 g to 10 g, and is preferably in the range of 0.7 g to 5 g per day for adults. The range of is more preferable.
In the composition (II) of the present invention, the dose (intake) of cystine is usually in the range of 0.28 g to 2 g, preferably in the range of 0.28 g to 1.5 g, and 0.28 g per day for adults. The range of ~ 1 g is more preferable.
The amount per adult can be appropriately changed in consideration of physical conditions such as gender, age, and disease.

In the composition (II) of the present invention, the above-mentioned daily amount can be administered (ingested) at one time or in several divided doses. The administration period (intake period) is not particularly limited, and long-term administration (long-term ingestion) is possible because the active ingredient is an amino acid.

In the composition (II) of the present invention, the proportion contained in the composition of amino acids other than tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine in the present invention is based on the total weight of the composition. In terms of free form, it is 50% by weight or less, preferably 40% by weight or less, more preferably 30% by weight or less, further preferably not substantially contained, and particularly preferably not contained. The term "substantially free" means 0.2% by weight or less, preferably 0.1% by weight or less, and more preferably 0.05% by weight or less.

The composition (II) of the present invention can further contain other nutritional components such as sugars, lipids, proteins, vitamins and minerals in addition to the amino acids in the present invention.

In addition to tyrosine, serine, alanine, aspartic acid, glutamate, isoleucine and cystine, the composition (II) of the present invention contains, if necessary, other amino acids, other nutritional components, food-acceptable additives, and pharmaceuticals. Add the additives, etc., which are permitted to be used, and use a formulation method well known in the field of formulation, for example, the method described in each article of the 17th revised Japanese Pharmacy Regulations [3] formulation, solution, suspension. It can be in various forms such as liquids such as liquids and emulsions; semi-solids such as gels and creams; solids such as powders, granules, tablets and capsules.

In the composition of the present invention, the above-mentioned food-acceptable additive or pharmaceutically acceptable additive can be appropriately selected depending on the form of the composition of the present invention, for example, excipients. Binders, disintegrants, lubricants, coatings, bases, solvents, solubilizers, solubilizers, emulsifiers, dispersants, suspending agents, stabilizers, thickeners, soothing agents, isotonic Examples thereof include agents, pH adjusters, antioxidants, preservatives, preservatives, flavoring agents, sweeteners, fragrances, colorants and the like.

Specifically, examples of the excipient include magnesium carbonate, sugars (glucose, lactose, cornstarch, etc.), sugar alcohols (sorbitol, mannitol, etc.) and the like.
Examples of the binder include gelatin, pregelatinized starch, partially pregelatinized starch, cellulose and its derivatives (crystalline cellulose, hydroxypropyl cellulose, etc.) and the like.
Examples of the disintegrant include crospovidone, povidone, crystalline cellulose and the like.
Examples of the lubricant include talc, magnesium stearate and the like.
Examples of the coating agent include methacrylic acid / methyl methacrylate copolymer, methacrylic acid / ethyl acrylate copolymer, methyl methacrylate / butyl methacrylate / dimethylaminoethyl methacrylate copolymer, ethyl acrylate / methacrylic acid. Examples thereof include a trimethylammonium ethyl methacrylate copolymer of methyl methacrylate.

Examples of the base include animal and vegetable fats and oils (olive oil, cacao butter, beef tallow, sesame oil, hydrogenated oil, castor oil, etc.), waxes (carnauba wax, beeswax, etc.), polyethylene glycol and the like.
Examples of the solvent include purified water, water for injection, monohydric alcohol (ethanol and the like), polyhydric alcohol (glycerin and the like) and the like.
Examples of the solubilizing agent include propylene glycol, medium-chain fatty acid triglyceride, and the like.

Examples of the solubilizer, emulsifier, dispersant and suspending agent include sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester (polysorbate 20, polysorbate 80, etc.), polyoxyethylene hydrogenated castor oil, and sucrose. Examples thereof include surfactants such as fatty acid esters.

Examples of the stabilizer include adipic acid, β-cyclodextrin, ethylenediamine, sodium edetate and the like.
Examples of the thickener include water-soluble polymers (sodium polyacrylate, carboxyvinyl polymer, etc.), polysaccharides (sodium alginate, xanthan gum, tragant, etc.) and the like.
Examples of the soothing agent include ethyl aminobenzoate, chlorobutanol, propylene glycol, benzyl alcohol and the like.
Examples of the tonicity agent include potassium chloride, sodium chloride, sorbitol, physiological saline and the like.
Examples of the pH adjuster include hydrochloric acid, sulfuric acid, acetic acid, citric acid, lactic acid, sodium hydroxide, potassium hydroxide and the like.

Examples of the antioxidant include dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), dl-α-tocopherol, erythorbic acid and the like.
Examples of preservatives and preservatives include parabens (methylparaben and the like), benzyl alcohol, sodium dehydroacetate, sorbic acid and the like.

Examples of the flavoring agent include ascorbic acid, erythritol, sodium L-glutamate and the like.
Examples of the sweetener include aspartame, licorice extract, saccharin and the like.
Examples of the fragrance include l-menthol, d-camphor, vanillin and the like.
Examples of colorants include tar pigments (edible red No. 2, edible blue No. 1, edible yellow No. 4, etc.), inorganic pigments (iron sesquioxide, iron yellow oxide, iron black oxide, etc.), and natural pigments (turmeric extract). , Β-carotene, sodium copper chlorophyllin, etc.) and the like.

In the present invention, one kind or two or more kinds of the above additives can be used.

The total content of tyrosine, serine, alanine, aspartic acid and glutamic acid in the composition (I) of the present invention is usually 10% by weight to 100% by weight based on the total amount of the composition from the viewpoint of functionality. It is preferably 50% by weight to 100% by weight, more preferably 60% by weight to 100% by weight, further preferably 70% by weight to 100% by weight, and particularly preferably 80% by weight to 100% by weight. ..

The total content of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine in the composition (II) of the present invention is usually 10% by weight to 100% by weight based on the total amount of the composition from the viewpoint of functionality. It is% by weight, preferably 50% by weight to 100% by weight, more preferably 60% by weight to 100% by weight, further preferably 70% by weight to 100% by weight, and particularly preferably 80% by weight to 100% by weight. By weight%.

The composition of the present invention may be in a "unit packaging form" in which the composition is packaged in units of one-time or one-meal intake. Such a form means a form in which the amount to be ingested per serving or one meal is predetermined and packaged. The container or package used in the unit packaging form can be appropriately selected depending on the form of the composition of the present invention, but a paper container or bag, a plastic container or bag, a pouch, an aluminum can, etc. Examples include steel cans, bottles, PET bottles, and PTP (press through pack) packaging sheets. For example, in the case of beverages, jelly, yogurt, gum, cookies, etc., there is a form in which one intake is packaged in a container such as a bag, pouch, bottle, box, etc., and in the case of granules, powder, slurry, etc. Examples include a form in which a single intake is individually wrapped in a pouch, a bag, or the like. In particular, when the composition is a health food, a food with a functional claim, a dietary supplement, a food for specified health use, etc., the composition of the present invention is packaged in the form of one intake or one intake unit per meal. Examples thereof include a form in which a beverage or jelly in which the composition of the present invention is suspended or dissolved is filled in a pouch or the like in the form of a single drink or a complete meal.

A total of 0.5 g to 4 g, preferably 0.5 g to 2 g of tyrosine, serine, alanine, aspartic acid and glutamic acid can be contained in the one-time or one-meal intake. As another embodiment, a total of 0.5 g to 4 g, preferably 0.5 g to 2 g of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine may be contained in the one-time or one-meal intake. it can.
As a result, the required amount of the amino acid can be easily ingested by ingesting one or one meal intake unit.

In yet another embodiment, a measuring container and a kit containing a composition containing tyrosine, serine, alanine, aspartic acid and glutamic acid as active ingredients, or a measuring container, and tyrosine, serine, alanine, aspartic acid and glutamic acid as active ingredients. , Kits containing compositions containing isoleucine and cystine.
The measuring container is not particularly limited as long as it is a container for measuring the single intake of the above amino acids, and examples thereof include a measuring cup and a measuring spoon. The amount to be ingested at one time is the same as the amount described in the unit packaging form per meal. The amount that can be measured with the measuring container can be determined according to the container, such as the amount of scraping or heaping. Further, the measuring container may have a scale on which the amount used at one time and the like are displayed.

The form of the composition of the present invention is liquid such as a beverage, jelly such as jelly, gel, jelly-like beverage, milky such as milk, milk beverage, yogurt, etc., gum-like, powdery, granular form. , Sheets, capsules, tablets, snack bars, solids such as cookies, etc.

Mammals (eg, humans, monkeys, mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, cows, horses, donkeys, pigs, sheep, etc.) and birds (eg, humans, monkeys, mice, rats, guinea pigs, horses, donkeys, pigs, sheep, etc.) , Duck, chicken, goose, turkey, etc.).
When the composition of the present invention is applied to an application target animal other than humans (hereinafter, also simply referred to as "target animal"), the intake or dose of the composition of the present invention is the type, sex, body weight, etc. of the target animal. It may be set appropriately according to.

The composition of the present invention can be added to various foods and ingested. The food to which the composition of the present invention is added is not particularly limited, and any food in a form generally used for meals or desserts may be used.
For example, the composition of the present invention can be added to a beverage such as a soft drink and, if desired, an appropriate flavor can be added to obtain a drink.
More specifically, the composition of the present invention may be added to, for example, soft drinks such as fruit juice drinks and sports drinks; dairy products such as milk and yogurt; confectionery such as jelly, chocolate, candy and biscuits. it can.

In the composition of the present invention, the total amount of amino acids (total amount converted into L-form and free form) in the present invention is the above-mentioned daily intake with respect to the above-mentioned various foods ingested per day. It is preferably added in an amount.

In addition, the composition of the present invention is a food product (hereinafter, also referred to as "food product of the present invention" in the present specification) by ordinary food manufacturing techniques, either as it is or by adding general food additives as needed. Can be provided as.
The food product of the present invention can be in various forms such as liquid, suspension, milky, gel, cream, powder, granule, sheet, capsule, tablet and the like.
Further, the food of the present invention is prepared by adding the composition of the present invention to various food raw materials, adding general food additives as necessary, and using a general food manufacturing technique to soften drinking water (fruit juice beverage). , Sports drinks, coffee drinks, tea drinks, etc.), dairy products (lactic acid bacteria drinks, fermented milk, butter, cheese, yogurt, processed milk, defatted milk, etc.), livestock meat products (ham, sausage, hamburger, etc.), fish paste products (ham, sausage, hamburger, etc.) Gamo, bamboo ring, fried satsuma, etc.), egg products (dashi roll, egg tofu, etc.), confectionery (cookies, jelly, chewing gum, candy, snack confectionery, cold confectionery, etc.) , Foods of various forms, may be bottled foods, canned foods, retort pouch foods.

Examples of the above food additives include manufacturing agents (citric acid, binders, etc.), thickening stabilizers (xanthan gum, sodium carboxymethyl cellulose, etc.), gelling agents (gelatin, agar, carrageenan, etc.), gum bases (vinyl acetate resin, vinyl acetate, etc.). Gelton, tickle, etc.), emulsifiers (glycerin fatty acid ester, sucrose fatty acid ester, saponin, lecithin, etc.), preservatives (benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, ε-polylysine, etc.), antioxidants (ε-polylysine, etc.) Ascorbic acid, erythorbic acid, catechin, etc.), brighteners (cellac, paraffin wax, beeswax, etc.), fungicides (thiaventazole, fludioxonyl, etc.), swelling agents (sodium hydrogencarbonate, gluconoδ-lactone, myoban, etc.), Sweeteners (aspartame, assesulfam potassium, kanzo extract, etc.), bitterness agents (caffeine, narringine, nigayomogi extract, etc.), acidulants (citric acid, tartaric acid, lactic acid, etc.), seasonings (sodium L-glutamate, 5' -Disodium inosinate, etc.), colorants (anato pigments, turmeric pigments, citrate pigments, etc.), fragrances (synthetic fragrances such as ethyl acetoacetate, anisaldehyde, natural fragrances such as orange and lavender) and the like.
In the present invention, one kind or two or more kinds of the above food additives can be used.

The food of the present invention can be suitably ingested by a wide range of subjects for the purpose of suppressing an increase in the amount of triglyceride in the liver or suppressing fatty liver.

Therefore, the food of the present invention is a food for specified health use, a food with a nutritional function, a food with a functional claim, or a sick person for suppressing an increase in the amount of neutral fat in the liver or for suppressing adipose liver. It can also be provided as food for special use such as food for the elderly, food for the elderly, health supplement, and the like. The food of the present invention includes, for example, a medical food for obesity and the like.

The food product of the present invention is ingested by the above-mentioned application target so that the total amount of amino acids in the present invention (total amount converted into L-form and free form) in the above-mentioned daily intake is the above-mentioned daily intake. It is preferable to let it.

The present invention will be described in more detail in the following examples, but the present invention is not limited to these examples.

[Test Example 1]
Serine, aspartic acid, alanine, glutamic acid, and tyrosine were mixed in the weight ratios shown in Table 1 to prepare the amino acid composition of Example 1. For serine, aspartic acid, alanine, glutamic acid, and tyrosine, L-form and free form were used.
Using BLACK6J male mice, obese mice were prepared from 6 weeks of age by loading with a high-fat, high-carbohydrate diet (Research Diet Co., Ltd. D12327).
From 8 weeks of age, the amino acid composition (1 g / kg body weight) and 0.5% methylcellulose solution (medium) of Example 1 were applied to the test group, and the 0.5% methylcellulose solution (medium) was applied to the control group in the morning and evening. Oral administration twice daily for 6 weeks. During this time, the diet used was a high-fat, high-carbohydrate diet.
In the normal group, using BLACK6J male mice, 0.5% methylcellulose solution (medium) was orally administered twice a day in the morning and evening from 8 weeks of age for 6 weeks. During this time, a control diet was used as the bait.
The group composition is shown in Table 2.
At 15 weeks of age, the liver was sampled under anesthesia, triglyceride (TG) in the liver was extracted by a conventional method, and quantified using a kit (WAKO). The results are shown in FIG.
In the control group, the amount of triglyceride (TG) was increased by the high-fat, high-carbohydrate diet as compared with the normal group, but in the test group to which the amino acid composition of Example 1 was administered, the amount of triglyceride (TG) was almost the same as that in the normal group. It was a quantity (Fig. 1). From this result, it was shown that the increase in triglyceride mass can be suppressed (returned to normal) by administration of the amino acid composition of Example 1.

[Test Example 2]
Serine, aspartic acid, alanine, glutamic acid, tyrosine, isoleucine, and cystine were mixed in the weight ratios shown in Table 3 to prepare the amino acid composition of Example 2. Serine, aspartic acid, alanine, glutamic acid, tyrosine, isoleucine, and cystine were L-form and free form.
KKAy male mice were used as the test group and the control group, and BLACK6J male mice were used as the normal group. The "KKAy mouse" is ^{a combined model in which the Ay} gene is introduced into the KK mouse, and is a mouse that expresses severe obesity and hyperglycemia earlier (7 to 8 weeks old) than the KK mouse.
KKAy male mice and BLACK6J male mice of the same age were bred from 6 weeks on a standard diet (Oriental Yeast Co., Ltd., AIN93G).
From 11 weeks of age, the test group (KKAy mouse) was a standard diet (Oriental yeast, AIN93G) mixed with 2% (w / w) of the amino acid composition of Example 2, and the control group (KKAy mouse) was a standard diet (KKAy mouse). The oriental yeast, AIN93G) and normal group (BLACK6J mice) were fed a standard diet (oriental yeast, AIN93G) for 5 weeks.
The group composition is shown in Table 4.
At 17 weeks of age, the liver was sampled under anesthesia, triglyceride (TG) in the liver was extracted by a conventional method, and quantified using a kit (WAKO). The results are shown in FIG.
In the control group, the amount of triglyceride (TG) was significantly increased as compared with the normal group, but in the test group to which the amino acid composition of Example 2 was administered, the amount of triglyceride (TG) was significantly decreased as compared with the control group. (Fig. 2). From this result, it was shown that the increase in triglyceride mass can be suppressed (approached to normal) by administration of the amino acid composition of Example 2.
Although obesity promotes fat accumulation in hepatocytes and exacerbates it by inflammation, the donation of the amino acid composition of Example 2 improved the increase in hepatic fat mass.

[Test Example 3]
The same amino acid composition of Example 2 used in Test Example 2 was used in Test Example 3.
Using BLACK6J male mice, they were bred on a high-fat diet (Oriental yeast, HFD-60) for 4 weeks from 10 weeks of age to prepare a diet-induced obesity model (DIO model).
From 14 weeks of age, the test group received a high-fat diet (HFD-60) mixed with 2% (w / w) of the amino acid composition of Example 2, and the control group received a high-fat diet (HFD-60). It was donated for 8 weeks.
The normal group was bred from 10 weeks of age on a standard diet (Oriental Yeast Co., Ltd., AIN93G) for 12 weeks using BLACK6J male mice.
The group composition is shown in Table 5.
At 23 weeks of age, the liver was sampled at autopsy, lipids in the liver were extracted by a routine method, and triglycerides and free fatty acids were quantified using a kit (WAKO). At the time of autopsy, epididymal fat, which is visceral fat, was collected and weighed. The results are shown in FIG.
Regarding the amount of triglyceride and free fatty acid in the liver, the amount of triglyceride and free fatty acid in the control group increased significantly as compared with the normal group, but in the test group to which the amino acid composition of Example 2 was administered, the amount was medium. The amount of triglyceride and the amount of free fatty acid were significantly reduced as compared with the control group (left and middle figures in FIG. 3). From this result, it was shown that the increase in the amount of fat in the liver can be suppressed (approached to normal) by the administration of the amino acid composition of Example 2.
Regarding the epididymal fat weight, the epididymal fat weight was significantly increased in the control group as compared with the normal group, but in the test group to which the amino acid composition of Example 2 was administered, the epididymal fat weight was increased in the control group. It decreased significantly (right figure in FIG. 3). From this result, it was shown that the increase in visceral fat mass can be suppressed (approached to normal) by administration of the amino acid composition of Example 2.
Although obesity promotes fat accumulation and visceral fat accumulation in hepatocytes, the donation of the amino acid composition of Example 2 improved the increase in liver fat mass and visceral fat mass.

[Test Example 4]
The same amino acid composition of Example 2 used in Test Example 2 was used in Test Example 4.
Using BLACK6J male mice, they were bred on a high-fat diet (Oriental yeast, HFD-60) for 4 weeks from 10 weeks of age to prepare a diet-induced obesity model (DIO model).
From 14 weeks of age, the test group received a high-fat diet (HFD-60) mixed with 2% (w / w) of the amino acid composition of Example 2, and the control group received a high-fat diet (HFD-60). It was donated for 8 weeks.
The normal group was bred from 10 weeks of age on a standard diet (Oriental Yeast Co., Ltd., AIN93G) for 12 weeks using BLACK6J male mice.
The group composition is shown in Table 6.
In the test group, tail vein blood sampling was performed at weeks 4, 6 and 8 of the high-fat diet (HFD-60) in which the amino acid composition of Example 2 was mixed at 2% (w / w), respectively, and fasting blood was collected. The medium insulin level was measured with a kit (Morinaga Seigaku Kenkyusho). In the normal group and the control group, blood was collected from the tail vein at the same time as the test group (14 weeks to 4, 6 and 8 weeks), and the fasting blood insulin level was used as a kit (Morinaga Seigaku Kenkyusho). Was measured. The results are shown in FIG.
In the control group, the fasting insulin level was significantly increased as compared with the normal group (left figure, middle figure, right figure in FIG. 4), but in the test group to which the amino acid composition of Example 2 was administered, the fasting insulin level was administered. However, it decreased significantly in the 4th and 6th weeks of the intervention compared to the control group (left figure and middle figure in FIG. 4), and decreased in the 8th week of the intervention as compared with the control group (right figure in FIG. 4). ).
An increase in fasting insulin levels suggests insulin resistance and decreased insulin sensitivity in organs. Insulin resistance promotes lipid accumulation in the liver. Diabetes induction is also inferred.
From the results of FIG. 4, it was shown that insulin resistance promoted by obesity can be improved (approached to normal) by administration of the amino acid composition of Example 2.
Obesity promotes insulin resistance, but donation of the amino acid composition of Example 2 improved insulin resistance.

This application is based on Japanese Patent Application No. 2019-220717 filed in Japan, the contents of which are all included in this application.

Claims

A composition containing tyrosine, serine, alanine, aspartic acid and glutamic acid as active ingredients to suppress an increase in the amount of triglyceride in the liver.
The composition according to claim 1, which is used for suppressing fatty liver.
Assuming that tyrosine is 1 part by weight, the compounding ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, 0.5 to 1.5 parts by weight of aspartic acid, and The composition according to claim 1 or 2, which is 0.4 to 2.5 parts by weight of glutamic acid.
The composition according to any one of claims 1 to 3, which is a food product.
A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine as active ingredients to suppress an increase in the amount of triglyceride in the liver.
The composition according to claim 5, which is used for suppressing fatty liver.
A composition for improving insulin resistance, which contains tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine as active ingredients.
A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine as active ingredients to suppress an increase in visceral fat mass.
Assuming that tyrosine is 1 part by weight, the compounding ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, 0.5 to 1.5 parts by weight of aspartic acid. The composition according to any one of claims 5 to 8, wherein the composition is 0.4 to 2.5 parts by weight of glutamic acid, 1 to 4 parts by weight of isoleucine, and 0.1 to 2 parts by weight of cystine.
The composition according to any one of claims 5 to 9, which is a food product.
A subject in need of suppression of an increase in triglyceride mass in the liver comprises administering a composition containing effective amounts of tyrosine, serine, alanine, aspartic acid and glutamic acid to the triglyceride in the liver. A method of suppressing the increase in quantity.
The method according to claim 11, wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
Assuming that tyrosine is 1 part by weight, the compounding ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, 0.5 to 1.5 parts by weight of aspartic acid, and The method according to claim 11 or 12, wherein the amount of glutamic acid is 0.4 to 2.5 parts by weight.
The method according to any one of claims 11 to 13, wherein the composition is orally administered to the subject.
A subject in need of suppression of the increase in triglyceride mass in the liver, which comprises administering a composition containing effective amounts of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine. A method of suppressing an increase in triglyceride mass.
The method according to claim 15, wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
Improving insulin resistance in a subject in need of improved insulin resistance, including administering to a subject a composition containing effective amounts of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine. Method.
Of the visceral fat mass in a subject in need of suppression of the increase in visceral fat mass, including administration of a composition containing effective amounts of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine. How to control the increase.
Assuming that tyrosine is 1 part by weight, the compounding ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, 0.5 to 1.5 parts by weight of aspartic acid. The method according to any one of claims 15 to 18, wherein the amount is 0.4 to 2.5 parts by weight of glutamic acid, 1 to 4 parts by weight of isoleucine, and 0.1 to 2 parts by weight of cystine.
The method according to any one of claims 15 to 19, wherein the composition is orally administered to a subject.
A composition containing tyrosine, serine, alanine, aspartic acid and glutamic acid for use in suppressing the increase in triglyceride mass in the liver.
The composition according to claim 21, wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
Assuming that tyrosine is 1 part by weight, the compounding ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, 0.5 to 1.5 parts by weight of aspartic acid, and so on. The composition according to claim 21 or 22, which is 0.4 to 2.5 parts by weight of glutamic acid.
The composition according to any one of claims 21 to 23, which is a food product.
A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine for use in suppressing the increase in triglyceride mass in the liver.
The composition according to claim 25, wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine for use in improving insulin resistance.
A composition containing tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine for use in suppressing an increase in visceral fat mass.
Assuming that tyrosine is 1 part by weight, the blending ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, 0.5 to 1.5 parts by weight of aspartic acid. The composition according to any one of claims 25 to 28, which comprises 0.4 to 2.5 parts by weight of glutamic acid, 1 to 4 parts by weight of isoleucine and 0.1 to 2 parts by weight of cystine.
The composition according to any one of claims 25 to 29, which is a food product.
Use of tyrosine, serine, alanine, aspartic acid and glutamic acid to produce compositions to suppress the increase in triglyceride mass in the liver.
The use according to claim 31, wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
Assuming that tyrosine is 1 part by weight, the compounding ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, 0.5 to 1.5 parts by weight of aspartic acid, and so on. The use according to claim 31 or 32, wherein the amount of glutamic acid is 0.4 to 2.5 parts by weight.
The use according to any one of claims 31 to 33, wherein the composition is a food product.
Use of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine to produce compositions for suppressing the increase in triglyceride mass in the liver.
The use according to claim 35, wherein the suppression of the increase in the amount of triglyceride in the liver is fatty liver suppression.
Use of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine to produce compositions to improve insulin resistance.
Use of tyrosine, serine, alanine, aspartic acid, glutamic acid, isoleucine and cystine to produce compositions to suppress the increase in visceral fat mass.
Assuming that tyrosine is 1 part by weight, the compounding ratio in the composition is 0.4 to 1.5 parts by weight of serine, 0.4 to 1.5 parts by weight of alanine, 0.5 to 1.5 parts by weight of aspartic acid. The use according to any one of claims 35 to 38, which is 0.4 to 2.5 parts by weight of glutamic acid, 1 to 4 parts by weight of isoleucine and 0.1 to 2 parts by weight of cystine.
The use according to any one of claims 35 to 39, wherein the composition is a food product.